参考文献/References:
1 Danen EH.Integrins:regulators of tissue function and cancer progression.Curr Pharm Des,2005,11(7):881-891.
2 Folkman J,Addressing tumor blood vessels.Nature Biotechnol,1997,15(6):510.
3 Kumar CC.Integrin αvβ3 as a therapeutic target for blocking tumor-induced angiogenesis.Curr Drug Targets,2003,4(2):123-131.
4 Teti A,Migliaccio S,Baron R.The role of alphavbeta3 integrin in the development of osteolytic bone metastases:a pharmacological target for alternative therapy?.Calcif Tissue Int,2002,71(4):293-299.
5 Raguse JD,Gath HJ,Bier J,et al.Gilengitide (EMD121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.Oral Oncol,2004,40(2):228-230.
6 Plersehbacher MD,Ruoslahti E.The cell attachment activity of flibronectin call be duplicated by small fragments of the molecule.Nature,1984,309:30-33
7 Van Hagen PM,Breeman WA,Bernard HF,et al.Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy.Int J Cancer,2000,90(4):186-198.
8 Haubner R,Wester HJ,Burkhart F,et al.Glycosylated RGD-containing peptides:tracer for tumor targeting and angiogenesis imaging with improved biokinetics.J Nucl Med,2001,42(2):326-336.
9 Haubner R,Wester HJ,Weber WA,et al.Noninvasive imaging of alpha(v) beta3 integrin expression using 18F-labeled RGD-containing giycopeptide and positron emission tomography.Cancer Res,2001,61(5):1781-1785.
10 Haubner R,Weber WA,Beer AJ,et al.Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.PLoS Med,2005,2(3):e70.
11 Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients.J Nucl Med,2005,46(8):1333-1341.
12 Chen X,Park R,Hou Y,et al,MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.Eur J Nucl Med Moi Imaging,2004,31(8):1081-1089.
13 Chen X,Park R,Tohme M,et al.MicroPET and autoradiographic imaging of breast cancer α v-integrin expression using 18F-and 64Cu-labeled RGD peptide.Bioconjug Chem,2004,15(1):41-49.
14 Chen X,Hou Y,Tohme M,et al.Pegylated Arg-Gly-Asp peptide:64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.J Nucl Med,2004,45(10):1776-1783.
15 Chen X,Liu S,Hou Y,et al.MicroPET imaging of breast cancer alpha v-integrin expression with 64Cu-labeled dimeric RGD peptides.Mol Imaging Biol,2004,6(5):350-359.
16 Chen X,Sievers E,Hou Y,et al.Integrin αvβ3-targeted imaging of lungcancer.Neoplasia,2005,7(3):271-279.
17 Dayton PA,Pearson D,Clark J,et al.Ultrasonic analysis of peptide-and antibody-targeted microbubble contrast agents for molecular imaging of αvβ3-expressing cells.Mol Imaging,2004,3(2):125-134.
18 Anderson SA,Rader RK,Westiin WF,et al.Magnetic resonance contrast enhancement of neovasculature with αvβ3-targeted nanoparli-cles.Magn Reson Med,2000,44(3):433-439.
19 Haubner R,Wester HJ.Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.Curr PharmDes,2004,10(13):1439-1455.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]刘晓飞,张锦明,王洁磊,等.放射性核素标记RGD序列多肽与整合素αvβ3受体显像的研究进展[J].国际放射医学核医学杂志,2008,32(1):12.
LIU Xiao-fei,ZHANG Jin-min,WANG Jie-lei,et al.Study progress of malignant tumor imaging of integrin αvβ3 expression with radioisotope labelled RGD peptides[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):12.